Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27316410 | 0.87 | HRH3 (0.39) | HRH3CYP2D6KCNH2 | |
| SCHEMBL23134802 | 0.84 | SMN1; SMN2 (0.36) | HRH3KCNH2ALDH1A1KDM4EPKM | |
| SCHEMBL15187957 | 0.82 | HRH3 (0.38) | HRH3CHRNA7CYP2D6KCNH2ALDH1A1 | |
| SCHEMBL20082919 | 0.81 | DPP4 (0.30) | — | |
| SCHEMBL24816727 | 0.81 | HRH3 (0.35) | HRH3CYP2D6 | |
| SCHEMBL23693864 | 0.80 | HRH3 (0.37) | HRH3CHRNA7CYP2D6KCNH2ALDH1A1 | |
| SCHEMBL8258502 | 0.77 | HRH3 (0.45) | HRH3CHRNA7CYP2D6KCNH2ALDH1A1 | |
| SCHEMBL26203701 | 0.77 | HRH3 (0.37) | HRH3CHRNA7CYP2D6KCNH2ALDH1A1 | |
| SCHEMBL20885450 | 0.75 | KDM2B (0.41) | HRH3CYP2D6KCNH2 | |
| SCHEMBL26347706 | 0.75 | KDM2B (0.41) | HRH3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230112012-A1 | FAP INHIBITOR | UNIVERSITAT HEIDELBERG (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | HNRNPR, HNRNPK, ATXN2 | HRH3 4258/4885CHRNA7 221/4885CYP2D6 4829/4885 |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | DPYD, TP53, GLS | HRH3 3789/4885CHRNA7 4650/4885CYP2D6 1010/4885 |
| US-20230112012-A1 | FAP INHIBITOR | FAP, APC, FIBP | HRH3 3752/4885CHRNA7 4726/4885CYP2D6 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.